Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD)

Read More

Source: Medical Xpress